An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis-Reference-Cited by-同舟云学术

An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis

Published:2020-02-07 Issue:6478 Volume:367 Page:652-660
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Zhao Peng¹^ORCID,Sun Xiaoli¹^ORCID,Chaggan Cynthia¹^ORCID,Liao Zhongji¹^ORCID,in Wong Kai¹,He Feng²,Singh Seema³,Loomba Rohit³,Karin Michael²^ORCID,Witztum Joseph L.¹^ORCID,Saltiel Alan R.¹²^ORCID

Affiliation:

1. Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

2. Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

3. NAFLD Research Center, Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

Abstract

Liver disease defect identified The energy sensor adenosine monophosphate–activated protein kinase (AMPK) is implicated in liver damage in nonalcoholic steatohepatitis (NASH), a leading cause of liver-associated death in humans. Zhao et al. used mouse models of NASH and samples from human NASH patients to show that AMPK, the activity of which is lost in NASH, phosphorylates the enzyme procaspase-6. In normal liver cells, this modification limits the activation of caspase-6 and the consequent caspase activation cascade that leads to apoptosis. AMPK and caspase-6 may thus provide therapeutic targets for the treatment of NASH. Science , this issue p. 652

Funder

U.S. Department of Defense

National Heart, Lung, and Blood Institute

National Institute of Diabetes and Digestive and Kidney Diseases

National Center for Advancing Translational Sciences

National Institute of Environmental Health Sciences

American Heart Association

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference41 articles.